H.R. 2319, Women and Lung Cancer Research and Preventive Services Act of 2025

August 14, 2025

Cost Estimate

As ordered reported by the House Committee on Energy and Commerce on April 29, 2025

H.R. 2319, Women and Lung Cancer Research and Preventive Services Act of 2025 As ordered reported by the House Committee on Energy and Commerce on April 29, 2025
By Fiscal Year, Millions of Dollars		2025	2025-2030	2025-2035
Direct Spending (Outlays)		0	0	0
Revenues		0	0	0
Increase or Decrease (-) in the Deficit		0	0	0
Spending Subject to Appropriation (Outlays)		*	*	not estimated
Increases net direct spending in any of the four consecutive 10-year periods beginning in 2036?	No	Statutory pay-as-you-go procedures apply?		No
	No	Mandate Effects
Increases on-budget deficits in any of the four consecutive 10-year periods beginning in 2036?	No	Contains intergovernmental mandate?		No
	No	Contains private-sector mandate?		No
* = between zero and $500,000.

H.R. 2319 would require the Department of Health and Human Services (HHS) to report to the Congress on research related to lung cancer in women and underserved populations as well as access to lung cancer screenings for those populations. HHS also would be required to report on public awareness campaigns related to lung cancer and lung cancer screenings. Based on the cost of similar reports, CBO estimates that implementing H.R. 2319 would cost less than $500,000 over the 2025-2030 period. Any related spending would be subject to the availability of appropriated funds.

The CBO staff contact for this estimate is Johnny Willing. The estimate was reviewed by Emily Stern, Senior Adviser for Budget Analysis.

Phillip L. Swagel Director, Congressional Budget Office

Phillip L. Swagel

Director, Congressional Budget Office